Subject(s)
Investments/statistics & numerical data , Research Support as Topic/economics , Research/economics , Unemployment/statistics & numerical data , Universities/economics , Budgets , COVID-19 , Coronavirus Infections/epidemiology , Education, Distance/economics , Faculty/statistics & numerical data , Humans , Investments/economics , Investments/trends , Pandemics , Pneumonia, Viral/epidemiology , Students/statistics & numerical data , Unemployment/trendsABSTRACT
ABSTRACT Objective To evaluate the effect of the COVID-19 impacts on the activities of researchers in the field of Oral Medicine (OM) and Oral Pathology (OP). To assess the research activities and training of human resources by Brazilian productivity fellows in research (BPFR) in OM and OP in the COVID-19 Era. Material and Methods Thirty-six BPFR in OM and OP areas, funded by National Council for Scientific and Technological Development (CNPq), received a virtual structured questionnaire by e-mail, on the Google Forms (Google®) platform, with questions regarding research activities and training of human resources (supervision of undergraduate and postgraduate students), during the COVID-19 pandemic. From the thirty-six BPFR in OM and OP, twenty-seven (75.0%) answered the questionnaire. Results Most of them were males (n=20; 74.1%) and were distributed in four Brazilian regions and ten states of the federation, including the Federal District. Twenty-four (88.9%) BPFR reported having suspended clinical activities, while sixteen (59.3%) answered that histopathology practices are suspended. Twenty-five (92.6%) BPFR mentioned difficulties in conducting research projects and 55.5% stated having no difficulties in the supervision of undergraduates, master's and PhD students. Conclusion The current scenario may significantly impact the diagnosis of oral diseases in Brazil. Moreover, a decrease in the scientific production of BPFR in OM and OP in the coming years is also considered.
Subject(s)
Humans , Male , Female , Pathology, Oral , Research Support as Topic , Training Support , Brazil/epidemiology , Oral Medicine , COVID-19 , Research , Technological Development , Surveys and Questionnaires , Data Interpretation, Statistical , Workforce , MentoringSubject(s)
Biomedical Research/economics , Biomedical Research/legislation & jurisprudence , Budgets/legislation & jurisprudence , COVID-19 , International Cooperation/legislation & jurisprudence , Research Personnel , Research Support as Topic/legislation & jurisprudence , COVID-19/economics , COVID-19/epidemiology , Clinical Trials as Topic/economics , Humans , Research Personnel/economics , Research Personnel/psychology , Uncertainty , United Kingdom , Universities/economicsABSTRACT
ABSTRACT Objective To evaluate the effect of the COVID-19 impacts on the activities of researchers in the field of Oral Medicine (OM) and Oral Pathology (OP). To assess the research activities and training of human resources by Brazilian productivity fellows in research (BPFR) in OM and OP in the COVID-19 Era. Material and Methods Thirty-six BPFR in OM and OP areas, funded by National Council for Scientific and Technological Development (CNPq), received a virtual structured questionnaire by e-mail, on the Google Forms (Google®) platform, with questions regarding research activities and training of human resources (supervision of undergraduate and postgraduate students), during the COVID-19 pandemic. From the thirty-six BPFR in OM and OP, twenty-seven (75.0%) answered the questionnaire. Results Most of them were males (n=20; 74.1%) and were distributed in four Brazilian regions and ten states of the federation, including the Federal District. Twenty-four (88.9%) BPFR reported having suspended clinical activities, while sixteen (59.3%) answered that histopathology practices are suspended. Twenty-five (92.6%) BPFR mentioned difficulties in conducting research projects and 55.5% stated having no difficulties in the supervision of undergraduates, master's and PhD students. Conclusion The current scenario may significantly impact the diagnosis of oral diseases in Brazil. Moreover, a decrease in the scientific production of BPFR in OM and OP in the coming years is also considered.
Subject(s)
Humans , Male , Female , Pathology, Oral , Research Support as Topic , Training Support , Brazil/epidemiology , Oral Medicine , COVID-19 , Research , Technological Development , Surveys and Questionnaires , Data Interpretation, Statistical , Workforce , MentoringABSTRACT
Thousands of UK doctoral students and early-career researchers shared the repercussions of lockdown on their work and wellbeing.
Subject(s)
Coronavirus Infections/prevention & control , Pandemics/prevention & control , Pneumonia, Viral/prevention & control , Research Personnel/psychology , Social Isolation , Workplace , Administrative Personnel/psychology , Burnout, Psychological , COVID-19 , Career Mobility , Efficiency , Emotions , Female , Humans , Loneliness/psychology , Male , Research Personnel/economics , Research Support as Topic , Social Media , Social Support , Stress, Psychological/epidemiology , Stress, Psychological/etiology , Surveys and Questionnaires , United Kingdom/epidemiology , Universities , Work Performance , Work-Life BalanceABSTRACT
In this Neuron Q&A, Xiang Yu talks about the stress and anxiety brought to the lab by the pandemic, the new opportunities for teaching and scientific conferences it created, the value of the individual, and the social responsibility of science for humanity and society to shape a brighter future.
Subject(s)
Neurosciences/trends , Beijing , COVID-19 , China , History, 21st Century , Pandemics , Research Support as TopicSubject(s)
COVID-19 , Diplomacy , Leadership , National Institutes of Health (U.S.)/organization & administration , Racism/prevention & control , Biomedical Research/economics , Biomedical Research/legislation & jurisprudence , Biomedical Research/organization & administration , COVID-19/complications , COVID-19/epidemiology , China , Female , Fetal Research/legislation & jurisprudence , Financing, Organized , Humans , International Cooperation , Male , National Institutes of Health (U.S.)/economics , Research Support as Topic , United StatesSubject(s)
Global Health/standards , International Agencies/organization & administration , International Health Regulations , Pandemics/prevention & control , Security Measures/legislation & jurisprudence , COVID-19/epidemiology , COVID-19/mortality , Forecasting , Global Health/legislation & jurisprudence , Humans , Information Dissemination , International Cooperation , International Health Regulations/standards , Pandemics/legislation & jurisprudence , Research Support as Topic/organization & administration , Security Measures/standards , World Health Organization/organization & administrationABSTRACT
Contemporary science has become increasingly multi-disciplinary and team-based, resulting in unprecedented growth in biomedical innovation and technology over the last several decades. Collaborative research efforts have enabled investigators to respond to the demands of an increasingly complex 21st century landscape, including pressing scientific challenges such as the COVID-19 pandemic. A major contributing factor to the success of team science is the mobilization of core facilities and shared research resources (SRRs), the scientific instrumentation and expertise that exist within research organizations that enable widespread access to advanced technologies for trainees, faculty, and staff. For over 40 years, SRRs have played a key role in accelerating biomedical research discoveries, yet a national strategy that addresses how to leverage these resources to enhance team science and achieve shared scientific goals is noticeably absent. We believe a national strategy for biomedical SRRs-led by the National Institutes of Health-is crucial to advance key national initiatives, enable long-term research efficiency, and provide a solid foundation for the next generation of scientists.
Subject(s)
Biomedical Research/organization & administration , COVID-19 , Intersectoral Collaboration , National Institutes of Health (U.S.)/organization & administration , Pandemics , SARS-CoV-2 , Academies and Institutes/organization & administration , Career Mobility , Congresses as Topic , Humans , Policy , Program Evaluation , Research Support as Topic , Societies, Scientific/organization & administration , Stakeholder Participation , United States , Universities/organization & administrationSubject(s)
Biomedical Research , COVID-19 , Career Mobility , Diabetes Mellitus , Research Personnel , Research Support as Topic , Humans , SARS-CoV-2 , United KingdomABSTRACT
Early-career researchers feel discouraged from exposing vulnerability even during a global crisis.
Subject(s)
Coronavirus Infections/prevention & control , Pandemics/prevention & control , Pneumonia, Viral/prevention & control , Research Personnel/psychology , Authorship , Burnout, Professional/etiology , Burnout, Professional/prevention & control , Burnout, Professional/psychology , COVID-19 , Career Mobility , Competitive Behavior , Economic Competition , Efficiency , Emotions , Humans , Publishing/statistics & numerical data , Research Personnel/economics , Research Support as Topic , Self Care , Self Concept , Social Isolation , Travel , Work Performance , WorkplaceSubject(s)
COVID-19/epidemiology , Guillain-Barre Syndrome/epidemiology , Case-Control Studies , Epidemiological Monitoring , Ethics Committees, Research , Ethics, Research , Guillain-Barre Syndrome/diagnosis , Guillain-Barre Syndrome/therapy , Humans , Information Dissemination , Pandemics , Research Support as Topic , SARS-CoV-2 , Time FactorsABSTRACT
The COVID-19 pandemic has revealed myriad and complex challenges for our national health care system spanning preparedness, response, access, costs, infrastructure, coordination, and medical innovation. These challenges implicate federal, state, and local agencies and actors, as well as international collaborative bodies. One constant throughout the pandemic has been the pressing need for safe and effective diagnostics, prophylactic vaccines, and drug treatments to counter the virus.1 Inarguably, significant problems with the multi-faceted system of drug and vaccine innovation and regulation manifested long before the COVID-19 pandemic.2 The pandemic, however, has laid bare the inextricable connections among federal funding, patents, product review and approval mechanisms, and the eventual medical products and resulting costs.